Seleziona una pagina

 

 

TEAM

Tracey Pirali

Tracey Pirali

CTO, Medicinal Chemist

tracey.pirali@chemicare.it

Tracey Pirali was born in Borgomanero (NO), Italy on November 28, 1978. She received her Master Degree in Pharmaceutical Chemistry and Technology (110/110 cum laude) and her PhD in Science of Bioactive Compounds from the Università del Piemonte Orientale (Novara, Italy) in 2007. After a stay at the CNRS in Gif-sur-Yvette (Paris) under the guidance of Prof. Jieping Zhu, in 2008 she was appointed Assistant Professor at the Università del Piemonte Orientale. In 2011 she spent her sabbatical as a Visiting Professor at the School of Chemistry in Edinburgh with Prof. Michael Greaney. In 2012 she received the Farmindustria Prize by the Italian Chemical Society. Currently, she is Associate Professor of Medicinal Chemistry at the Università del Piemonte Orientale, where her main research interest is the design and synthesis of bioactive compounds via multicomponent reactions and click chemistry, with a focus on Store Operated Calcium Entry, TRP channels and indoleamine 2,3-dioxygenase. She has published over 30 papers and holds three patent applications. She is member of the Scientific Committee of the European School of Medicinal Chemistry (ESMEC). In 2016 she co-founded the Start Up ChemICare.

 

Beatrice Riva

Beatrice Riva

CEO, Pharmacologist

beatrice.riva@chemicare.it

Beatrice Riva was born in Biella (BI), Italy on May 2, 1986. She received her Master Degree in Medical and Pharmaceutical Biotechnologies (108/110) and her PhD in Science of Bioactive Compounds from the Università del Piemonte Orientale (Novara, Italy) in 2014. After a PhD under the guidance of Prof. Fabrizio Condorelli, where she deepened her studies on chronic myeloid leukemia, she became Postdoctoral Researcher in the laboratory of Prof. Armando Genazzani. Currently, she is a Postdoctoral Researcher in Pharmacology. Her research interests include: (i) assessment of the mechanisms underlying the peripheral neuropathy induced by oxaliplatin and evaluation of new drugs to treat neuropathy; (ii) identification of molecules with therapeutic activities for some rare diseases related to gain-of-function mutations in calcium channels. In 2016 she co-founded the Start Up ChemICare.

 

University Career

Since 2016 Associate Professor, Università del Piemonte Orientale (UPO)

2008-2016 Assistant Professor, Università del Piemonte Orientale (UPO)

2007-2008 Post-Doctoral Researcher, Università del Piemonte Orientale (UPO)

Main Fields of Interest

  1. Drug discovery and development / 2. Click chemistry / 3. Multicomponent reactions / 4. Aryne chemistry

Top three papers

  • “Identification of a Potent Phosphoinositide 3-​Kinase Pan Inhibitor Displaying a Strategic Carboxylic Acid Group and Development of Its Prodrugs” Pirali T., Ciraolo E., Aprile S., Massarotti, A., Berndt, A., Griglio, A., Serafini, M., Mercalli V., Landoni C., Campa C.C., Margaria J.P.; Silva R. L., Grosa G.; Sorba, G., Williams R., Hirsch E., Tron, G.C. ChemMedChem 2017, 12, 1542-1554
  • “Transition-Metal-Free Synthesis of 2-Arylimidazolones via Cascade Reaction between Arynes and α,α’ Disubstituted α-Isocyanoacetamides” Gesù A., Pozzoli C. Torre E., Aprile, S.,Pirali, T. Organic Letters 2016 18, 1992-1995
  • “Transition-Metal-Free Direct Arylation of Anilines” Pirali T., Zhang F., Miller A. H., Head J. L., McAusland D., Greaney M. F. Angewandte Chemie International Edition 2012 51, 1006-1009
University Career

Since 2015 Postdoctoral Researcher, Università del Piemonte Orientale (UPO)

2010-2014 PhD student in Science of Bioactive Compounds, Università del Piemonte Orientale (UPO)

Main Fields of Interest

  1. Drug Discovery / 2. Calcium signalling  / 3. Calcium channels as molecular targets

Pubblications

  • “Calcium-related Neurotoxicity of Oxaliplatin: Understanding the Mechanisms to Drive Therapy” Marmiroli P., Cavaletti G., Carozzi V., Riva B., Lim D., Genazzani A. A Current Medicinal Chemistry 2015, 22, 3682-3684
  • “A novel gain-of-function mutation in ORAI1 causes late-onset Tubular Aggregate Myopathy and congenital miosis” Garibaldi m., Fattori F., Riva B., Labasse C., Brochier G., Ottaviani P., Sacconi S., Vizzaccaro E., Laschena F., Romero N., Genazzani A. A., Bertini E., Antonini G. Clin Genet. 2017, 91, 780-786 
  • “Celecoxib inhibits proliferation and survival of Chronic Myelogeous Leukemia (CML) blasts via AMPK-dependent regulation of β-catenin and mTORC1/2” Riva B., De Dominici M., Gnemmi I, Mariani S. A., Minassi A., Minieri V., Salomoni P., Canonico P. L., Genazzani A. A., Calabretta B., and Condorelli F. Oncotarget 2016, 7, 81555-81570
  • “Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights” Marmiroli P., Riva B., Pozzi E., Ballarini E., Lim D., Chiorazzi A., Meregalli C., Distasi C., Renn CL., Semperboni S., Morosi L., Ruffinatti FA., Zucchetti M., Dorsey SG., Cavaletti G., Genazzani A., Carozzi VA. PLoS One. 2017, 12(10):e0186250

 

 

Celia Cordero Sanchez

Technician

celia.sanchez@chemicare.it

Degree in Biotechnology and Bioengineering at Miguel Hernández University of Elche, Alicante (Spain). Celia worked for 2 years in the area of channelopathies of calcium channels, searching for modulators of TRPM8 by High Throughput Screening (HTS), under the guidance of Prof. Asia Fernández Carvajal. During her studies, Celia spent three months at the Department of Pharmaceutical Sciences of the Università del Piemonte Orientale, (Novara, Italy) where she worked on the discovery and biological evaluation of modulators of the Stored-Operated Calcium Entry. Currently, she works as a researcher for ChemICare. She performes the cellular and molecular biology experiments for the characterization of new small-molecule modulators.

 

 

TEAM

Tracey Pirali

Tracey Pirali

CTO, Medicinal Chemist

tracey.pirali@chemicare.it

Tracey Pirali was born in Borgomanero (NO), Italy on November 28, 1978. She received her Master Degree in Pharmaceutical Chemistry and Technology (110/110 cum laude) and her PhD in Science of Bioactive Compounds from the Università del Piemonte Orientale (Novara, Italy) in 2007. After a stay at the CNRS in Gif-sur-Yvette (Paris) under the guidance of Prof. Jieping Zhu, in 2008 she was appointed Assistant Professor at the Università del Piemonte Orientale. In 2011 she spent her sabbatical as a Visiting Professor at the School of Chemistry in Edinburgh with Prof. Michael Greaney. In 2012 she received the Farmindustria Prize by the Italian Chemical Society. Currently, she is Associate Professor of Medicinal Chemistry at the Università del Piemonte Orientale, where her main research interest is the design and synthesis of bioactive compounds via multicomponent reactions and click chemistry, with a focus on Store Operated Calcium Entry, TRP channels and indoleamine 2,3-dioxygenase. She has published over 30 papers and holds three patent applications. She is member of the Scientific Committee of the European School of Medicinal Chemistry (ESMEC). In 2016 she co-founded the Start Up ChemICare.

 

University Career

Since 2016 Associate Professor, Università del Piemonte Orientale (UPO)

2008-2016 Assistant Professor, Università del Piemonte Orientale (UPO)

2007-2008 Post-Doctoral Researcher, Università del Piemonte Orientale (UPO)

Main Fields of Interest

  1. Drug discovery and development / 2. Click chemistry / 3. Multicomponent reactions / 4. Aryne chemistry

Top three papers

  • “Identification of a Potent Phosphoinositide 3-​Kinase Pan Inhibitor Displaying a Strategic Carboxylic Acid Group and Development of Its Prodrugs” Pirali T., Ciraolo E., Aprile S., Massarotti, A., Berndt, A., Griglio, A., Serafini, M., Mercalli V., Landoni C., Campa C.C., Margaria J.P.; Silva R. L., Grosa G.; Sorba, G., Williams R., Hirsch E., Tron, G.C. ChemMedChem 2017, 12, 1542-1554
  • “Transition-Metal-Free Synthesis of 2-Arylimidazolones via Cascade Reaction between Arynes and α,α’ Disubstituted α-Isocyanoacetamides” Gesù A., Pozzoli C. Torre E., Aprile, S.,Pirali, T. Organic Letters 2016 18, 1992-1995
  • “Transition-Metal-Free Direct Arylation of Anilines” Pirali T., Zhang F., Miller A. H., Head J. L., McAusland D., Greaney M. F. Angewandte Chemie International Edition 2012 51, 1006-1009
Beatrice Riva

Beatrice Riva

CEO

beatrice.riva@chemicare.it

Beatrice Riva was born in Biella (BI), Italy on May 2, 1986. She received her Master Degree in Medical and Pharmaceutical Biotechnologies (108/110) and her PhD in Science of Bioactive Compounds from the Università del Piemonte Orientale (Novara, Italy) in 2014. After a PhD under the guidance of Prof. Fabrizio Condorelli, where she deepened her studies on chronic myeloid leukemia, she became Postdoctoral Researcher in the laboratory of Prof. Armando Genazzani. Currently, she is a Postdoctoral Researcher in Pharmacology. Her research interests include: (i) assessment of the mechanisms underlying the peripheral neuropathy induced by oxaliplatin and evaluation of new drugs to treat neuropathy; (ii) identification of molecules with therapeutic activities for some rare diseases related to gain-of-function mutations in calcium channels. In 2016 she co-founded the Start Up ChemICare.

 

University Career

Since 2015 Postdoctoral Researcher, Università del Piemonte Orientale (UPO)

2010-2014 PhD student in Science of Bioactive Compounds, Università del Piemonte Orientale (UPO)

Main Fields of Interest

  1. Drug Discovery / 2. Calcium signalling  / 3. Calcium channels as molecular targets

Pubblications

  • “Calcium-related Neurotoxicity of Oxaliplatin: Understanding the Mechanisms to Drive Therapy” Marmiroli P., Cavaletti G., Carozzi V., Riva B., Lim D., Genazzani A. A Current Medicinal Chemistry 2015, 22, 3682-3684
  • “A novel gain-of-function mutation in ORAI1 causes late-onset Tubular Aggregate Myopathy and congenital miosis” Garibaldi m., Fattori F., Riva B., Labasse C., Brochier G., Ottaviani P., Sacconi S., Vizzaccaro E., Laschena F., Romero N., Genazzani A. A., Bertini E., Antonini G. Clin Genet. 2017, 91, 780-786 
  • “Celecoxib inhibits proliferation and survival of Chronic Myelogeous Leukemia (CML) blasts via AMPK-dependent regulation of β-catenin and mTORC1/2” Riva B., De Dominici M., Gnemmi I, Mariani S. A., Minassi A., Minieri V., Salomoni P., Canonico P. L., Genazzani A. A., Calabretta B., and Condorelli F. Oncotarget 2016, 7, 81555-81570
  • “Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights” Marmiroli P., Riva B., Pozzi E., Ballarini E., Lim D., Chiorazzi A., Meregalli C., Distasi C., Renn CL., Semperboni S., Morosi L., Ruffinatti FA., Zucchetti M., Dorsey SG., Cavaletti G., Genazzani A., Carozzi VA. PLoS One. 2017, 12(10):e0186250
Celia Cordero Sanchez

Celia Cordero Sanchez

Technician

celia.sanchez@chemicare.it

Degree in Biotechnology and Bioengineering at Miguel Hernández University of Elche, Alicante (Spain). Celia worked for 2 years in the area of channelopathies of calcium channels, searching for modulators of TRPM8 by High Throughput Screening (HTS), under the guidance of Prof. Asia Fernández Carvajal. During her studies, Celia spent three months at the Department of Pharmaceutical Sciences of the Università del Piemonte Orientale, (Novara, Italy) where she worked on the discovery and biological evaluation of modulators of the Stored-Operated Calcium Entry. Currently, she works as a researcher for ChemICare. She performes the cellular and molecular biology experiments for the characterization of new small-molecule modulators.

 

PARTNERS

 

 

 

10 + 2 =

ChemICare srl  – P:IVA 02302680034

Via Amico Canobio 4/6, Novara

info@chemicare.it

Informativa cookies